ID   COLO201-AR
AC   CVCL_4V91
DR   cancercelllines; CVCL_4V91
DR   Wikidata; Q54814209
RX   PubMed=21098728;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1987 ! COLO 201
SX   Male
AG   70Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 10
//
RX   PubMed=21098728; DOI=10.1126/scisignal.2001148;
RA   Corcoran R.B., Dias-Santagata D., Bergethon K., Iafrate A.J.,
RA   Settleman J., Engelman J.A.;
RT   "BRAF gene amplification can promote acquired resistance to MEK
RT   inhibitors in cancer cells harboring the BRAF V600E mutation.";
RL   Sci. Signal. 3:Ra84.1-Ra84.10(2010).
//